As on 07-Dec-2023 09:42 EST
$0.63
$0.63
$0.64
$0.63
7,887
$0.51 - 3.28
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Trevena (TRVN)
| -54.94 | 11.30 | -35.56 | -75.02 | -77.81 | -47.56 | -- |
S&P BSE Sensex
| 14.27 | 7.02 | 5.53 | 11.01 | 15.54 | 14.51 | 12.72 |
#
| -- | -- | -- | -- | -- | -- | -- |
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
---|---|---|---|---|---|---|---|
Trevena (TRVN)
| -90.19 | -72.76 | 154.49 | 95.56 | -72.93 | -72.79 | -44.00 |
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of Trevena Inc. (TRVN) stood at $ 46 Mln as on 31-Mar-23
The share price of Trevena Inc. (TRVN) is $0.64 (NASDAQ) as of 07-Dec-2023 09:42 EST. Trevena Inc. (TRVN) has given a return of -77.81% in the last 3 years.
Trevena Inc. (TRVN) has a market capitalisation of $ 12 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Trevena Inc. (TRVN) is 0.57 times as on 02-Jun-2023, a -0.78% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Trevena Inc. (TRVN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Trevena Inc. (TRVN) and enter the required number of quantities and click on buy to purchase the shares of Trevena Inc. (TRVN).
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
The CEO & director of Ms. Carrie L. Bourdow. is Trevena Inc. (TRVN), and CFO & Sr. VP is Mr. Barry Shin.
The promoters of Trevena Inc. (TRVN) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
483
|
|
9
|
|
7
|
|
4
|
Trevena Inc. (TRVN) | Ratios |
---|---|
Return on equity(%)
|
-271.18
|
Return on capital employed(%)
|
--
|
Debt-to-equity ratio
|
1.33
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Trevena Inc. (TRVN) was $-30 Mln.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G... protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. Read more
Sign up and get access to:
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.